Drug Profile
DCB BO1202
Alternative Names: DCB-BO1202Latest Information Update: 28 Jan 2022
Price :
$50
*
At a glance
- Originator GoldenMed BioTechnology
- Class Antifibrotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatic fibrosis
Most Recent Events
- 28 Jan 2022 No recent reports of development identified for preclinical development in Hepatic-fibrosis in Taiwan (PO, Capsule)
- 10 Jan 2020 Preclinical development is ongoing in Taiwan (NCT02289300)
- 10 Jan 2020 A2 Healthcare Taiwan Corporation and GoldenMed Biotechnology withdraw prior to enrolment, a phase II trial in Hepatic fibrosis in Taiwan (PO) (sponsor's discretion) (NCT02289300)